VANCOUVER, British Columbia, April 02, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” Where “core one”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) thanks to a research agreement with Neuro-Zone Srl, (“Neuro-Zone”) based in Bresso, Italy, has achieved positive results from its in vitro biological test (“bioassay“) development studies (“bioassay studies”); advance the company’s patent-pending psychedelic bioactive compounds that could lead to breakthrough drug formulations for Alzheimer’s disease (AD), Parkinson’s disease (PD), major depressive disorder (depression) and Stroke, (collectively “targeted diseases” Where “neurological indications”).
Bioassay studies are one of the most important tools in the discovery and development of new drugs because they identify whether a compound or, in Akome’s research scenarios, bioactive compounds, have the effect desired on the targeted pathological pathways.
Neuro-Zone bioassay studies have, to date, focused on confirming the relationship between plant bioactives covered by patent applications filed with the United States Patent and Trademark Office ( USPTO) of Akome (namely AKO001, AKO002, AKO003, and AKO004 (see Company press releases dated June 19, 2021, May 6, 2021, July 21, 2021, and July 26, 2021, respectively), and neuropathological mechanisms under related to conditions such as AD, PD, depression and stroke.
Neuro-Zone’s bioassay studies have allowed researchers to assess the effect of Akome’s plant bioactives on various biological targets associated with the neurological indications in question. Positive results from bioassay studies indicate that Akome’s plant bioactives possess the desired biological effects against the neuropathological mechanisms of Alzheimer’s disease, as well as other neuro-inflammatory processes.
Building on these positive results, Akome and Neuro-Zone are actively developing the next steps in the Company’s drug development process.
“The positive results of these studies have demonstrated that Akome is making significant strides towards developing breakthrough drug formulations that can be used to treat neurological diseases. This is great news for the tens of millions of people affected by Alzheimer’s disease, Parkinson’s disease, depression and stroke, around the world,” said Joel Shacker, CEO of the company.
Neuro-Zone is a functional services company supporting drug discovery and research projects in the areas of inflammation and age-related pathologies, including the mechanisms underlying common brain diseases. With their in-depth, value-added scientific knowledge and state-of-the-art technology platforms, Neuro-Zone studies cell-cell interactions and biological activity of the Company’s novel drug candidates and provides an understanding of the role of the microenvironment in the scenarios of complex diseases.
About Core One Labs Inc.
Core One Labs is a life science biotechnology research and development company focused on bringing psychedelic drugs to market through the development and production of psychedelic compounds, the advancement of psychedelic-assisted treatments, and the integration new technologies of administration systems.
The company has a multi-faceted business approach and integrates multiple business lines and complementary units to establish itself as an industry leader in the emerging and rapidly growing psychedelics market.
Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection for a proprietary psilocybin production system using engineered bacteria. It also holds 4 provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental disorders, under its wholly owned subsidiary Akome Biotech Ltd., and 3 provisional patents under its other wholly owned subsidiary , Awakened Biosciences. Inc., for additional synthetic technologies for psilocybin and psilocin production methods.
In addition to the development of psychedelics and psychedelic compounds, Core One has interests in four medical clinics that maintain a combined database of over 275,000 patients. Through its clinics, the Company intends to integrate a deployment of its intellectual property related to psychedelic technologies and participate in the advancement of psychedelic-based treatments for mental health disorders.
Core One Labs Inc.
Chief Executive Officer
FOR MORE INFORMATION PLEASE CONTACT:
The Canadian Securities Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the content of this press release.
The information in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the Company’s control. These factors include, among others: the risks and uncertainties associated with the Company’s limited operating history and the need to comply with stringent regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied by the forward-looking information. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking information.
In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offense to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One has no direct or indirect involvement in the illegal sale, production or distribution of psychedelic substances in the jurisdictions in which it operates. Although Core One believes that psychedelics can be used to treat certain medical conditions, it does not advocate the legalization of psychedelics for recreational use. Core One does not deal with psychedelics except in laboratory and clinical trials conducted under approved regulatory frameworks.